Showing 126–150 of 278
FY2025 revenue $16.31bn (+5.9%); operating margin 13.4%; net income $1.36bn.
Cash $1.98bn; debt $15.72bn.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Parent Johnson & Johnson (JNJ) group FY2025 revenue $94.19bn (+6.0%); pre-tax margin 34.6%; net income $26.80bn.
MedTech segment sales $33.79bn (+6.1%).
FY2026 revenue £431.1m (+17.4%); operating margin 12.7%; net income £42.5m.
No debt; £89.1m cash.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
FY2025 revenue ¥1.09tn (-3.6%); operating margin 4.6%; net income ¥30.3bn.
Continuing operations; returned to operating profit from a ¥64.0bn loss.
FY2025 revenue £63.3m (-5.1%).
Adjusted EBITDA £11.3m (from £15.8m); £21.6m cash, no debt.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Parent Danaher (DHR) group FY2025 revenue $24.57bn (+3.0%); operating margin 19.1%; net income $3.60bn.
Figures cover the whole listed group, not this business alone.
Listed (328130.KQ).
Latest full-year results not yet captured by HSH.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
FY2025 revenue $1.53bn (+9.4%).
Preliminary revenue only; full GAAP results not yet captured.
Recent change of ownership; current owner not yet confirmed from official filings.
Financial health not assessed until ownership and accounts are verified.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Part of Dassault Systèmes (DSY.PA).
Latest full-year results not yet captured by HSH.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
FY2026 revenue $36.36bn (+8.4%); operating margin 17.8%; net income $4.80bn.
Balance sheet figures not captured from release.